Floatz logo

Dual-Target Antigen-Selected Car-Nk

Pancreatic Ductal Adenocarcinoma

Essen BiotechCell therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

282 Active assets in the Pancreatic Ductal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Rmc-6236
Tango Therapeutics, Inc.
Phase 3BB
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
OHSU Knight Cancer Institute
Phase 2BB
Daraxonrasib
Revolution Medicines, Inc.
Phase 3BB
S-1
Genentech, Inc.
Phase 2BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Dual-Target Antigen-Selected Car-Nk is also rated in:

prostate cancerDormant
CCC
Indicative ·
48 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
47 / 100
View asset →
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →